Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress
05 Mai 2023 - 10:00PM
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical
company focused on the discovery, development and commercialization
of precision medicines for kidney diseases, today announced
upcoming data presentations at the 60th ERA Congress from June 15 –
18, 2023, both virtual and live in Milan, Italy. The five accepted
abstracts will be delivered as three focused orals (digital poster
with 3-minute presentation), one free communication (10-minute live
oral presentation) and one moderated oral presentation (6-slide
presentation).
Chinook will host a live conference call and webcast on Friday,
June 16, 2023 at 8:15 am EDT to review and discuss the abstracts
and provide corporate updates. Members of the Chinook executive
team will be joined by Jonathan Barratt, PhD, FRCP, Mayer Professor
of Renal Medicine at University of Leicester in Leicester, UK for a
discussion on Chinook’s programs.
Focused Orals:
Abstract Title: |
Updated Interim Results of a Phase 1/2 Study of BION-1301
in Patients with IgA Nephropathy |
Presenting Author: |
Jonathan Barratt, PhD,
FRCPUniversity of Leicester & Leicester General Hospital,
Leicester, UK |
Session: |
Glomerular &
Tubulo-interstitial Diseases |
Date/Time/Location: |
Friday, June 16, 2023 at 8:30 –
9:45 am CEST, FO Room 2 |
|
|
Abstract
Title: |
A Phase 3, Randomized,
Double-blind, Placebo-controlled Study of BION-1301 in Adults with
IgA Nephropathy |
Presenting Author: |
Vlado Perkovic, MBBS, PhD, FRACP,
FASNUniversity of New South Wales, Sydney, New South Wales,
Australia |
Session: |
Glomerular &
Tubulo-interstitial Diseases |
Date/Time/Location: |
Friday, June 16, 2023 at 12:00 –
1:15 pm CEST, FO Room 9 |
|
|
Abstract
Title: |
ASSIST Study Design: A
Randomized, Double-blind, Placebo-controlled, Crossover Study of
Atrasentan in Patients with IgA Nephropathy (IgAN) on
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) |
Presenting Author: |
Hiddo J. L Heerspink, PhD,
PharmDUniversity Medical Center Groningen, Groningen,
Netherlands |
Session: |
Glomerular &
Tubulo-interstitial Diseases |
Date/Time/Location: |
Friday, June 16, 2023 at 8:30 –
9:45 am CEST, FO Room 2 |
|
|
Free Communication:
Abstract Title: |
CHK-336, A First-in-Class Orally Administered LDH
Inhibitor: Safety, PK and Target Engagement in a First-in-Human
Phase 1 Healthy Volunteer Study |
Presenting Author: |
Vincent Tong, PhDChinook
Therapeutics |
Session: |
Something Rare, Something
Special |
Date/Time/Location: |
Saturday, June 17, 2023 at 12:00
– 1:15 pm CEST, Amber 3 & 4 |
|
|
Moderated Oral:
Abstract Title: |
Accumulation of Maladaptive Tubular Epithelial Cells (TECs)
is Ubiquitous in Chronic Kidney Diseases and Represents a Common
Initiating Mechanism of Disease Progression |
Presenting Author: |
Eric Olson, PhDChinook
Therapeutics |
Session: |
Moderated Orals 1.4 |
Date/Time/Location: |
Friday, June 16, 2023 at 2:00 –
3:15 pm CEST, Amber 6 |
|
|
For more information on these and other abstracts, please visit
the 60th ERA Congress website.
Investor Conference Call DetailsTo access the
call, please dial (800) 715-9871 (domestic) or (646) 307-1963
(international) and provide the Conference ID 3321571 to the
operator.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit
the Investors section of Chinook’s website. The archived
webcast will remain available for replay on Chinook’s website for
90 days.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, a phase 3
endothelin receptor antagonist for the treatment of IgA nephropathy
and proteinuric glomerular diseases. BION-1301, an anti-APRIL
monoclonal antibody, is being evaluated in a phase 1/2 trial for
IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for
the treatment of hyperoxalurias, is in phase 1 development. In
addition, Chinook’s research and discovery efforts are focused on
building a pipeline of precision medicines for rare, severe chronic
kidney diseases with defined genetic and molecular drivers. Chinook
is leveraging insights from kidney single cell RNA sequencing and
large CKD patient cohorts that have been comprehensively
panomically phenotyped, with retained biosamples and prospective
clinical follow-up, to discover and develop therapeutic candidates
with mechanisms of action targeted against key kidney disease
pathways. To learn more, visit www.chinooktx.com.
Cautionary Note on Forward-Looking
StatementsCertain of the statements made in this press
release are forward looking, including those relating to Chinook’s
business, future operations, advancement of its product candidates
and product pipeline, clinical development of its product
candidates, including expectations regarding cash forecasts and
timing of initiation and results of clinical trials, and regulatory
submissions, including the timing of the results of our phase 3
ALIGN trial and phase 2 AFFINITY trial of atrasentan, phase 3
clinical trial of BION-1301, phase 1/2 trial of BION-1301, the
resumption of dosing in our phase 1 clinical trial of CHK-336, and
submission for potential accelerated approval for atrasentan. In
some cases, you can identify these statements by forward-looking
words such as “may,” “will,” “continue,” “anticipate,” “intend,”
“could,” “project,” “expect” or the negative or plural of these
words or similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our ability to develop and commercialize our product candidates,
including initiation of clinical trials of our existing product
candidates or those developed as part of the Evotec collaboration
or other strategic collaborations, whether results of early
clinical trials or preclinical studies will be indicative of the
results of future trials, including our phase 3 ALIGN trial, our
ability to obtain and maintain regulatory approval of our product
candidates, our ability to operate in a competitive industry and
compete successfully against competitors that may be more advanced
or have greater resources than we do, our ability to obtain and
adequately protect intellectual property rights for our product
candidates, and the effects of macroeconomic conditions on our
business operations, including rising interest rates and inflation.
Many of these risks are described in greater detail in our filings
with the SEC. Any forward-looking statements in this press release
speak only as of the date of this press release. Chinook assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Investor Contact:
Noopur Liffick
Senior Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
Media Contact:
Kelly North
Senior Manager, Investor Relations & Corporate Communications
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Chinook Therapeutics (NASDAQ:KDNY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024